When was Amphista Therapeutics founded?

Amphista Therapeutics was founded in 2017 and raised its 1st funding round 3 years after it was founded.

Where is Amphista Therapeutics located?

Amphista Therapeutics is headquartered in Cambridge, United Kingdom. It is registered at 158-160 North Gower Street, London, England, NW1 2ND.

Which legal entities is Amphista Therapeutics associated with?

Amphista Therapeutics is associated with Amphista Therapeutics Limited.

How many employees does Amphista Therapeutics have?

As of May 31, 2026, the latest employee count at Amphista Therapeutics is 49.

Is Amphista Therapeutics a funded company?

Amphista Therapeutics is a funded company, having raised a total of $60.5M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 07, 2020.

How much is Amphista Therapeutics worth?

The latest valuation of Amphista Therapeutics is £***** as of Dec 12, 2022.

When was the latest funding round of Amphista Therapeutics?

Amphista Therapeutics' latest funding was a $***** Series B round on Dec 13, 2022, with participation from 1 investor.

What is the annual revenue of Amphista Therapeutics?

Annual revenue of Amphista Therapeutics is between £10M and £50M as on Dec 31, 2024

Where does Amphista Therapeutics rank among its competitors?

Amphista Therapeutics ranks 33rd amongst 2426 active competitors, of which 844 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Amphista Therapeutics?

Amphista Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Among them, Karyopharm secured the most recent funding round in March, 2026.

Amphista Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Amphista Therapeutics is a series B company based in Cambridge (United Kingdom), founded in 2017. It operates as a Developer of targeted protein degradation medicines for treating pathogenic proteins. Amphista Therapeutics has raised $60.5M in funding from investors like Forbion, Gilde Healthcare and Advent Life Sciences, with a current valuation of £*****. The company has 2426 active competitors, including 844 funded and 600 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines.

Company Details

Developer of targeted protein degradation medicines for treating pathogenic proteins. These therapeutics function by triggering the destruction and removal of specific proteins associated with disease progression. The technology utilizes rationally designed molecules to consolidate performance characteristics of traditional degradation approaches. This method enables the targeting of a wider scope of tissues and indications than conventional protein degradation techniques.

Website: amphista.com
Social
Email ID: *****@amphista.com
Registered Address: 158-160 North Gower Street, London, England, NW1 2ND

Key Metrics

Founded Year

2017

Location

Cambridge, United Kingdom

Stage

Series B

Total Funding

$60.5M in 3 rounds

Latest Funding Round

Series B, Dec 13, 2022, $*****

Post Money Valuation

£***** as on Dec 12, 2022

Investors

Forbion & 11 more

Ranked

33^rd among 2426 active competitors

Annual Revenue

£10M - £50M as on Dec 31, 2024

Employee Count

49 as on May 31, 2026

Similar Companies

Plexium & 24 more

View Amphista Therapeutics' full profile

Amphista Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Amphista Therapeutics Limited CIN: 11119959 , United Kingdom, Active		$10M - $50M (As on Dec 31, 2024)	56 (As on Dec 31, 2024)

Amphista Therapeutics has raised a total funding of $60.5M over 3 rounds. Its first funding round was on Apr 07, 2020. Its latest funding round was a Series B round on Dec 13, 2022 for $*****. 1 investor participated in its latest round. Amphista Therapeutics has 10 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Amphista Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 13, 2022	5127575	Series B	9723902	1313521	3336480	8116466
Mar 17, 2021	8950102	Series B	9857750	7286364	7257840	Novartis Venture Fund & 3 more
Apr 07, 2020	9301594	Series A	8450185	9261486	Advent Life Sciences	Scottish Enterprise & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Amphista Therapeutics's funding rounds and investors

Amphista Therapeutics' Board of Directors

Amphista Therapeutics's board has 7 active members. Louise Kelly Modis and Joshua Brumm are part of team and Rogier Wouter Rooswinkel, Bart Dzikowski, Stefan Emanuel Luzi, Christian Billy Jung and Dominic Schmidt are independent board members.

Here is the list of Amphista Therapeutics' board of directors:

Name	Type	Representing	Status	Duration
ihkpyzp	Team	-	Current	4y 1m
pdfkykk	Team	-	Current	3y 6m
Rogier Wouter Rooswinkel	Independent board member	-	Current	5y 2m
eziqaxy	Independent board member	-	Current	5y 6m
ghoofwn	Independent board member	-	Current	9y 5m
uozkmsg	Independent board member	-	Current	5y 7m
twdvkod	Independent board member	-	Current	2y 8m

Amphista Therapeutics' employee count trend

Amphista Therapeutics has 49 employees as of May 26. Here is Amphista Therapeutics's employee count trend over the years:

Employee count trend for Amphista Therapeutics

Uncover Amphista Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Amphista Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Here is the list of Top 10 competitors of Amphista Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
3rd	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 16 others	71/100
33rd	Amphista Therapeutics 2017, Cambridge (United Kingdom), Series B	Developer of targeted protein degradation medicines for treating pathogenic proteins	$60.5M	Advent Life Sciences, Lilly & 10 others	67/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Amphista Therapeutics's competitors? Click here to see the top ones

Amphista Therapeutics has made no investments or acquisitions yet.

Media has covered Amphista Therapeutics for a total of 13 events in the last 1 year, 9 of them have been about company updates and 2 about people movement.